SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1 | – | 50 | +900.0% | 0.00% | – |
| Q2 2023 | $0 | -100.0% | 5 | -98.2% | 0.00% | -100.0% |
| Q1 2023 | $12 | -45.5% | 285 | -49.5% | 0.01% | +11.1% |
| Q4 2022 | $22 | – | 564 | +7957.1% | 0.01% | – |
| Q3 2022 | $0 | – | 7 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 7 | -93.3% | 0.00% | -100.0% |
| Q1 2022 | $3,000 | -40.0% | 104 | -3.7% | 0.00% | -71.4% |
| Q4 2021 | $5,000 | – | 108 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |